A systematic review including 3666 HCC liver transplant recipients showed that CNI immunosuppressive regimens were associated with an increased risk of HCC recurrence compared to mTOR inhibitor-containing regimens (13.8% vs. 8.0%, p < 0.001) [114]. Here, MTOR is linked to hepatocellular carcinoma.